SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $280,659,981 | -6.3% | 10,179,905 | +2.2% | 0.01% | 0.0% |
| Q2 2023 | $299,410,317 | -13.0% | 9,960,423 | +4.9% | 0.01% | -20.0% |
| Q1 2023 | $344,162,173 | +0.5% | 9,499,370 | -1.1% | 0.01% | -9.1% |
| Q4 2022 | $342,606,497 | +9.8% | 9,604,892 | +4.2% | 0.01% | 0.0% |
| Q3 2022 | $311,983,000 | +22.6% | 9,216,574 | +4.8% | 0.01% | +37.5% |
| Q2 2022 | $254,383,000 | -11.5% | 8,796,145 | -1.1% | 0.01% | 0.0% |
| Q1 2022 | $287,311,000 | +16.6% | 8,889,575 | +5.2% | 0.01% | +33.3% |
| Q4 2021 | $246,431,000 | +4.3% | 8,451,022 | -4.6% | 0.01% | -14.3% |
| Q3 2021 | $236,263,000 | -13.5% | 8,858,737 | -0.2% | 0.01% | -12.5% |
| Q2 2021 | $273,171,000 | +16.0% | 8,872,052 | -1.4% | 0.01% | +14.3% |
| Q1 2021 | $235,467,000 | +5.0% | 8,994,226 | +0.9% | 0.01% | 0.0% |
| Q4 2020 | $224,247,000 | +18.5% | 8,912,801 | -1.8% | 0.01% | 0.0% |
| Q3 2020 | $189,214,000 | -10.5% | 9,079,322 | +2.0% | 0.01% | -12.5% |
| Q2 2020 | $211,475,000 | +37.4% | 8,904,300 | +4.1% | 0.01% | 0.0% |
| Q1 2020 | $153,893,000 | -25.7% | 8,554,255 | -2.1% | 0.01% | 0.0% |
| Q4 2019 | $207,191,000 | -9.1% | 8,734,832 | +5.4% | 0.01% | -20.0% |
| Q3 2019 | $227,813,000 | -15.9% | 8,290,127 | +1.2% | 0.01% | -16.7% |
| Q2 2019 | $270,995,000 | -4.0% | 8,189,577 | +1.7% | 0.01% | -7.7% |
| Q1 2019 | $282,248,000 | +5.2% | 8,055,030 | -0.3% | 0.01% | -7.1% |
| Q4 2018 | $268,272,000 | -33.4% | 8,075,659 | +0.9% | 0.01% | -17.6% |
| Q3 2018 | $402,951,000 | -12.5% | 8,003,001 | +4.1% | 0.02% | -19.0% |
| Q2 2018 | $460,287,000 | +42.1% | 7,690,669 | +8.7% | 0.02% | +40.0% |
| Q1 2018 | $323,898,000 | +17.8% | 7,071,947 | +2.5% | 0.02% | +15.4% |
| Q4 2017 | $275,054,000 | +1.4% | 6,902,230 | +1.8% | 0.01% | -7.1% |
| Q3 2017 | $271,272,000 | -6.4% | 6,781,836 | +0.8% | 0.01% | -6.7% |
| Q2 2017 | $289,962,000 | +38.3% | 6,727,641 | +0.5% | 0.02% | +25.0% |
| Q1 2017 | $209,595,000 | +192189.0% | 6,696,310 | +156173.3% | 0.01% | – |
| Q4 2016 | $109,000 | -6.0% | 4,285 | -8.6% | 0.00% | – |
| Q3 2016 | $116,000 | +19.6% | 4,688 | -1.1% | 0.00% | – |
| Q2 2016 | $97,000 | +148.7% | 4,742 | +81.8% | 0.00% | – |
| Q1 2016 | $39,000 | +178.6% | 2,608 | +156.9% | 0.00% | – |
| Q4 2015 | $14,000 | +55.6% | 1,015 | +54.5% | 0.00% | – |
| Q3 2015 | $9,000 | -18.2% | 657 | 0.0% | 0.00% | – |
| Q2 2015 | $11,000 | +22.2% | 657 | -14.3% | 0.00% | – |
| Q1 2015 | $9,000 | +50.0% | 767 | 0.0% | 0.00% | – |
| Q4 2014 | $6,000 | -14.3% | 767 | 0.0% | 0.00% | – |
| Q3 2014 | $7,000 | -12.5% | 767 | 0.0% | 0.00% | – |
| Q2 2014 | $8,000 | – | 767 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |